# Arcadia Biosciences, Inc.: financial statements, quarterly

RKDA · Nasdaq · CIK 1469443 · [Energy](/sectors/energy.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/rkda.md) · [Financials](/companies/rkda/financials.md) · [Filings](/companies/rkda/filings.md) · [Insiders](/companies/rkda/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/rkda/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [1,298](/filings/0000950170-24-125613.md) | [777 d](/filings/0000950170-25-044487.md) | [987](/filings/0000950170-25-066425.md) | [1,306](/filings/0000950170-25-109040.md) | [1,537](/filings/0001193125-25-272375.md) | [1,216 d](/filings/0001193125-26-126238.md) | [1,200](/filings/0001193125-26-223990.md) | [1,455](/filings/0001193125-26-349205.md) | [1,302](/filings/0001193125-25-272375.md) | [901 d](/filings/0001193125-26-126238.md) | [1,100](/filings/0001193125-26-223990.md) | [1,443](/filings/0001193125-26-349205.md) |
| Cost of revenue | $k | [818](/filings/0000950170-24-125613.md) | [178 d](/filings/0000950170-25-044487.md) | [471](/filings/0000950170-25-066425.md) | [633](/filings/0000950170-25-109040.md) | [1,032](/filings/0001193125-25-272375.md) | [827 d](/filings/0001193125-26-126238.md) | [682](/filings/0001193125-26-223990.md) | [824](/filings/0001193125-26-349205.md) | [884](/filings/0001193125-25-272375.md) | [709 d](/filings/0001193125-26-126238.md) | [700](/filings/0001193125-26-223990.md) | [812](/filings/0001193125-26-349205.md) |
| Research and development | $k | [15.0](/filings/0000950170-24-125613.md) | [9.0 d](/filings/0000950170-25-044487.md) | [6.0](/filings/0000950170-25-066425.md) | [10.0](/filings/0000950170-25-109040.md) | [24.0](/filings/0001193125-25-272375.md) | [13.0 d](/filings/0001193125-26-126238.md) | [0.0](/filings/0000950170-25-066425.md) | [9.0](/filings/0001193125-26-349205.md) | [0.0](/filings/0001193125-25-272375.md) | [0.0 d](/filings/0001193125-26-126238.md) | not reported | [0.0](/filings/0001193125-26-349205.md) |
| Selling, general and administrative | $k | [1,862](/filings/0000950170-24-125613.md) | [1,699 d](/filings/0000950170-25-044487.md) | [2,062](/filings/0000950170-25-066425.md) | [2,683](/filings/0000950170-25-109040.md) | [2,241](/filings/0001193125-25-272375.md) | [2,655 d](/filings/0001193125-26-126238.md) | [1,738](/filings/0001193125-26-223990.md) | [2,123](/filings/0001193125-26-349205.md) | [1,570](/filings/0001193125-25-272375.md) | [1,567 d](/filings/0001193125-26-126238.md) | [1,179](/filings/0001193125-26-223990.md) | [1,127](/filings/0001193125-26-349205.md) |
| Operating income | $k | [(1,397)](/filings/0000950170-24-125613.md) | [(1,193) d](/filings/0000950170-25-044487.md) | [(1,588)](/filings/0000950170-25-066425.md) | [1,980](/filings/0000950170-25-109040.md) | [(1,760)](/filings/0001193125-25-272375.md) | [(2,279) d](/filings/0001193125-26-126238.md) | [530](/filings/0001193125-26-223990.md) | [(501)](/filings/0001193125-26-349205.md) | [(1,152)](/filings/0001193125-25-272375.md) | [(1,375) d](/filings/0001193125-26-126238.md) | [(779)](/filings/0001193125-26-223990.md) | [(496)](/filings/0001193125-26-349205.md) |
| Interest expense | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $k | [0.0](/filings/0000950170-24-125613.md) | [7.0 d](/filings/0000950170-25-044487.md) | not reported | [0.0](/filings/0000950170-24-096439.md) | [0.0](/filings/0000950170-24-125613.md) | [8.0 d](/filings/0001193125-26-126238.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $k | [(2,567)](/filings/0000950170-24-125613.md) | [(2,853) d](/filings/0000950170-25-044487.md) | [(2,423)](/filings/0000950170-25-066425.md) | [1,061](/filings/0000950170-25-109040.md) | [(1,612)](/filings/0001193125-25-272375.md) | [(4,064) d](/filings/0001193125-26-126238.md) | [2,599](/filings/0001193125-26-223990.md) | [(4,458)](/filings/0001193125-26-349205.md) | [856](/filings/0001193125-25-272375.md) | [(1,336) d](/filings/0001193125-26-126238.md) | [(4,385)](/filings/0001193125-26-223990.md) | [(6,266)](/filings/0001193125-26-349205.md) |
| Diluted EPS | $ per share | [(1.89)](/filings/0000950170-24-125613.md) | not reported | [(1.78)](/filings/0000950170-25-066425.md) | [0.78](/filings/0000950170-25-109040.md) | [(1.18)](/filings/0001193125-25-272375.md) | not reported | [1.90](/filings/0001193125-26-223990.md) | [(3.26)](/filings/0001193125-26-349205.md) | [0.62](/filings/0001193125-25-272375.md) | not reported | [(2.11)](/filings/0001193125-26-223990.md) | [(2.09)](/filings/0001193125-26-349205.md) |
| Basic EPS | $ per share | [(1.89)](/filings/0000950170-24-125613.md) | not reported | [(1.78)](/filings/0000950170-25-066425.md) | [0.78](/filings/0000950170-25-109040.md) | [(1.18)](/filings/0001193125-25-272375.md) | not reported | [1.90](/filings/0001193125-26-223990.md) | [(3.26)](/filings/0001193125-26-349205.md) | [0.63](/filings/0001193125-25-272375.md) | not reported | [(2.11)](/filings/0001193125-26-223990.md) | [(2.09)](/filings/0001193125-26-349205.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [10.6](/filings/0000950170-23-062216.md) | [6.5](/filings/0000950170-25-044487.md) | [3.3](/filings/0000950170-24-058563.md) | [5.5](/filings/0000950170-24-096439.md) | [3.9](/filings/0000950170-24-125613.md) | [4.2](/filings/0001193125-26-126238.md) | [3.2](/filings/0000950170-25-066425.md) | [1.4](/filings/0000950170-25-109040.md) | [1.1](/filings/0001193125-25-272375.md) | [0.3](/filings/0001193125-26-349205.md) | [1.0](/filings/0001193125-26-223990.md) | [4.2](/filings/0001193125-26-349205.md) |
| Current assets | $m | [20.0](/filings/0000950170-23-062216.md) | [15.0](/filings/0000950170-25-044487.md) | [11.6](/filings/0000950170-24-058563.md) | [12.4](/filings/0000950170-24-096439.md) | [10.7](/filings/0000950170-24-125613.md) | [9.2](/filings/0001193125-26-126238.md) | [8.8](/filings/0000950170-25-066425.md) | [7.6](/filings/0000950170-25-109040.md) | [8.4](/filings/0001193125-25-272375.md) | [6.4](/filings/0001193125-26-349205.md) | [5.2](/filings/0001193125-26-223990.md) | [5.7](/filings/0001193125-26-349205.md) |
| Total assets | $m | [23.5](/filings/0000950170-23-062216.md) | [19.7](/filings/0000950170-25-044487.md) | [16.0](/filings/0000950170-24-058563.md) | [17.4](/filings/0000950170-24-096439.md) | [15.2](/filings/0000950170-24-125613.md) | [13.5](/filings/0001193125-26-126238.md) | [13.0](/filings/0000950170-25-066425.md) | [7.8](/filings/0000950170-25-109040.md) | [8.6](/filings/0001193125-25-272375.md) | [6.5](/filings/0001193125-26-349205.md) | [5.3](/filings/0001193125-26-223990.md) | [5.9](/filings/0001193125-26-349205.md) |
| Current liabilities | $m | [3.9](/filings/0000950170-23-062216.md) | [3.6](/filings/0000950170-25-044487.md) | [2.9](/filings/0000950170-24-058563.md) | [2.7](/filings/0000950170-24-096439.md) | [2.3](/filings/0000950170-24-125613.md) | [2.6](/filings/0001193125-26-126238.md) | [2.2](/filings/0000950170-25-066425.md) | [1.8](/filings/0000950170-25-109040.md) | [2.3](/filings/0001193125-25-272375.md) | [2.1](/filings/0001193125-26-349205.md) | [1.4](/filings/0001193125-26-223990.md) | [1.6](/filings/0001193125-26-349205.md) |
| Total liabilities | $m | [8.1](/filings/0000950170-23-062216.md) | [7.0](/filings/0000950170-25-044487.md) | [5.6](/filings/0000950170-24-058563.md) | [5.8](/filings/0000950170-24-096439.md) | [5.1](/filings/0000950170-24-125613.md) | [7.3](/filings/0001193125-26-126238.md) | [4.1](/filings/0000950170-25-066425.md) | [3.3](/filings/0000950170-25-109040.md) | [3.1](/filings/0001193125-25-272375.md) | [2.4](/filings/0001193125-26-349205.md) | [2.4](/filings/0001193125-26-223990.md) | [5.3](/filings/0001193125-26-349205.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [15.5](/filings/0000950170-23-062216.md) | [12.8](/filings/0000950170-25-044487.md) | [10.6](/filings/0000950170-24-058563.md) | [11.7](/filings/0000950170-24-096439.md) | [10.3](/filings/0000950170-24-125613.md) | [6.2](/filings/0000950170-25-044487.md) | [8.9](/filings/0001193125-26-349205.md) | [4.5](/filings/0001193125-26-349205.md) | [5.4](/filings/0001193125-25-272375.md) | [4.1](/filings/0001193125-26-349205.md) | [2.9](/filings/0001193125-26-349205.md) | [0.6](/filings/0001193125-26-349205.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity, us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(2,885) d](/filings/0000950170-24-125613.md) | [(4,145) d](/filings/0000950170-25-044487.md) | [(3,210)](/filings/0000950170-25-066425.md) | [(2,456) d](/filings/0000950170-25-109040.md) | [(1,752) d](/filings/0001193125-25-272375.md) | [(2,209) d](/filings/0001193125-26-126238.md) | [(1,588)](/filings/0001193125-26-223990.md) | [(2,033) d](/filings/0001193125-26-349205.md) | [(257) d](/filings/0001193125-25-272375.md) | [(822) d](/filings/0001193125-26-349205.md) | [(1,099)](/filings/0001193125-26-223990.md) | [(319) d](/filings/0001193125-26-349205.md) |
| Capital expenditure | $k | [0.0 d](/filings/0000950170-24-125613.md) | [0.0 d](/filings/0000950170-25-044487.md) | [13.0](/filings/0000950170-25-066425.md) | [3.0 d](/filings/0000950170-25-109040.md) | [0.0 d](/filings/0001193125-25-272375.md) | [0.0 d](/filings/0001193125-26-126238.md) | [0.0](/filings/0000950170-25-066425.md) | [0.0 d](/filings/0000950170-25-109040.md) | [0.0 d](/filings/0001193125-25-272375.md) | [0.0 d](/filings/0001193125-26-126238.md) | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | thousands of shares | [614](/filings/0000950170-23-062216.md) | [864](/filings/0000950170-24-058563.md) | [1,358](/filings/0000950170-24-096439.md) | [1,360](/filings/0000950170-24-125613.md) | [1,362](/filings/0000950170-25-066425.md) | [1,363](/filings/0000950170-25-109040.md) | [1,364](/filings/0001193125-25-272375.md) | [1,366](/filings/0001193125-26-223990.md) | [1,367](/filings/0001193125-26-349205.md) | [1,372](/filings/0001193125-25-272375.md) | [2,083](/filings/0001193125-26-223990.md) | [2,993](/filings/0001193125-26-349205.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 2,409,211 at 2026-08-06, from the cover of the [10-Q filed 2026-08-13](/filings/0001193125-26-349205.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:40 ET. No prices; not investment advice.